Why Lilly is betting on peripheral pain biology with the 4E Therapeutics acquisition
Find out how Lilly’s 4E Therapeutics deal could advance non-opioid chronic pain drugs and what risks remain.
Pharma & Biotech
Pharma & Biotech
Can Almirall turn dermatology momentum into a stronger long-term innovation engine?
Almirall’s dermatology engine is growing faster than group sales. The next test is whether biologics and pipeline bets can sustain momentum.
Pharma & Biotech
Lilly’s $3.5bn Pennsylvania site will anchor U.S. manufacturing for next-gen injectables including retatrutide
Eli Lilly and Company has announced a $3.5 billion investment to build a new injectable medicine and device manufacturing facility in Lehigh Valley, Pennsylvania. The site will focus on producing next-generation weight-loss medicines, including the investigational triple hormone receptor agonist retatrutide. Set to become operational by 2031, this is Lilly’s fourth new U.S. manufacturing site